Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Oncologist Sees Need to Seek Middle Ground towards CGP Testing for 1st Line Therapy
The oncology community needs to devise ways to better push its case for introducing comprehensive genomic profiling (CGP) testing for frontline cancer treatments in a bid to make such proposal get through in the reimbursement reform next year, an oncologist…
To read the full story
Related Article
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- CGP Assays Prior to Initial Treatment Would Have Little Impact on Health Finances: Professor
May 31, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
ACADEMIA
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…